% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • NhanDuyVo NhanDuyVo Jun 13, 2012 9:00 PM Flag

    SGEN will soar like REGN

    With ADC technology niche, SGEN will change the way how cancer treatment can be done with little side effects.

    Adcetris commercial is well done and will become a blockbuster drug. Adcetris clinical trials for other indications provide significant validation of the ADC platform.

    I can see SGEN will soar like REGN soon. Hold your shares tight.

    All the best!


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Not to quibble, but REGN is down 24% from its recent high. Are you suggesting that SGEN could drop below $20 again?

      • 2 Replies to elsielind
      • I think you intended to get me wrong.

        Let take a look at the revenue and EPS projected for REGN as well as last year earnings. You can see that REGN forward revenue is around $1b for 2012... and I think that SGEN will be there next year or so with label expansion and other revenues from collaborations and indications with partners.

        The future for SGEN is very bright!

      • riceenseenmstoknowethefuture riceenseenmstoknowethefuture Jun 15, 2012 6:15 AM Flag

        This was from the " Riceen Letter".

        SGEN will be at $25,25 on June 15th. It will end the month over $30.00.

        "This collaboration is directly aligned with our goal of identifying novel ADC targets to expand our early-stage product pipeline," said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. "Through the agreement, we contribute our know-how and proprietary ADC technology and gain access to novel cancer targets obtained from OBT's expertise in target discovery. We believe that this type of multi-product collaboration maximizes the chances for success and capitalizes on each company's strengths."

        "We are delighted to be collaborating with Seattle Genetics in this alliance which we believe will add multiple ADC candidates to OBT's rapidly developing pre-clinical product pipeline. ADCs are beginning to transform the outlook for many cancer patients and OBT believes that with its antibody pipeline, it can make an important contribution to the development of this exciting new class of therapeutics. We are looking forward to working with Seattle Genetics to provide improved therapies for patients suffering from cancer," said Christian Rohlff, Chief Executive Officer of OBT.

        Under the terms of the multi-year, multi-product agreement, OBT and Seattle Genetics will each have an equal number of alternating options to select programs from among the preclinical ADCs identified for exclusive, worldwide development and commercialization. Each company will receive undisclosed progress-dependent milestone payments and royalties on net sales of any resulting ADCs developed by the other party.


43.17+0.96(+2.27%)Nov 27 1:00 PMEST